Jakavi 15mg Tablet
Marketer
Novartis India Ltd
Salt Composition
Ruxolitinib (15mg)
Overview Jakavi 15mg Tablet
Ruxolitinib 15mg tablets are indicated for managing chronic myelofibrosis and polycythemia vera. Optimal absorption occurs regardless of food intake, however, consistent daily timing maximizes therapeutic effects. Dosage and frequency are determined individually by your physician based on your specific condition and may be adjusted. Strict adherence to your doctor's prescription is crucial; improper use can lead to severe adverse reactions. While benefits might not be immediately apparent (taking several weeks or months), discontinue use only under your doctor's instruction. Common side effects include headache, lightheadedness, and thrombocytopenia. This medication can lower blood cell counts, raising infection risk. Regular blood work monitoring is essential, including blood cell counts, hepatic, renal, and lipid profiles. Inform your physician of any pre-existing liver or kidney disease, or concurrent medications, particularly anti-infectives. Drug interactions are possible; disclose all medications to your healthcare provider. This medication is contraindicated during pregnancy and breastfeeding. Reliable contraception is vital for both partners throughout treatment. A patient support program exists in India, facilitated by Tata 1mg; consult your doctor or call (1800-102-1618) for further information.
Primary Ingredients of Jakavi 15mg Tablet
No text provided. Please provide the text you wish to be rephrased.
Uses of Jakavi 15mg Tablet
Essential thrombocythemia and myelofibrosis
Major Benefits of Jakavi 15mg Tablet:
Administer this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment duration. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Jakavi 15mg tablets can be consumed with or without food, although consistent timing is recommended.
Common Side effects of Jakavi 15mg Tablet:
- Headache
- Dizziness
- Low blood platelets
- Anemia (low number of red blood cells)
How to use Jakavi 15mg Tablet:
Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment duration. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Jakavi 15mg tablets can be administered with or without food; however, consistent daily timing is recommended.
How Jakavi 15mg Tablet works:
Ruxolitinib 15mg tablets are a cancer treatment. Their mechanism involves inhibiting the activity of a faulty protein responsible for signaling uncontrolled cancer cell growth, thereby hindering or reducing cancer progression.
SAFETY ADVICE
AlcoholSAFE
There are no known adverse interactions between Jakavi 15mg tablets and alcohol consumption.
PregnancyCONSULT YOUR DOCTOR
Ruxolitinib 15mg tablets might pose risks during pregnancy. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the advantages against potential hazards prior to prescribing. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
Ruxolitinib 15mg tablets are likely unsuitable for use while breastfeeding. Available human data indicates potential transfer of the medication into breast milk, posing a possible risk to the infant.
DrivingUNSAFE
Taking a 15mg Jakavi tablet might reduce attentiveness, impair vision, or cause drowsiness and dizziness. Driving should be avoided if these effects are experienced.
KidneyCAUTION
Patients with kidney impairment should use Jakavi 15mg tablets cautiously, potentially requiring dosage modification. Physician consultation is recommended. Jakavi 15mg tablets are contraindicated for individuals with moderate to severe kidney disease.
LiverCAUTION
Ruxolitinib 15mg tablets require careful administration in individuals with hepatic impairment. Dosage modification of ruxolitinib 15mg tablets may be necessary. Physician consultation is advised.
What if you forget to take Jakavi 15mg Tablet :
NA
Facts to Know About Jakavi 15mg Tablet
| Label | Value |
|---|---|
| Chemical Category | Pyrrolo[2,3-d]pyrimidine derivative |
| Developing Habits | No. |
| Type of Therapy | Cancer Medications |
| Actions | Kinase inhibitors targeting tyrosine |
3,018 People bought this recently